It is so obvious, all the volume and it never moves up because of UBSS. Before that SBSH. Who and WHY is anyone buying this? I am willing to bet anyone $50 PayPal that Jeff does and RS this year.

In October 2006, 1 million shares of AXGJ was worth $90,000 give or take (My first buy was at .09). March 2007, less then 6 months away, your 1 million shares are worth $500.

The chart was setup thats for sure.

UBSS has a printing press. Some of these stocks we can only guess if they dilute. Jeff, listen up buddy, it is very obvious what you are doing.

Ben obviously doesn't play the pinks!

Keeping Your Cool in a Shaky Market by Ben Stein

Now for a few lessons from the recent stock market zaniness:

1. Don't panic. Panicky behavior, especially panicky buying and selling, accomplishes absolutely nothing. Smart investors never buy in a rush or sell in a rush. It's always worthwhile to think, to consider, and to do research. Only madmen and stock traders and speculators panic. Don't do it.

2. Keep plenty of cash on hand at all times. It's very hard to think rationally about stocks if every dime you have is in stocks and if the market is falling fast. The risks of annihilation are so great at that point that panicked selling seems like a smart option.

If you keep a good chunk of your assets in cash, bonds, and money market funds, however, so that you know you'll be safe, sane, and secure for a long time to come no matter how the market is gyrating, you can make a patient, sensible evaluation of the situation.

Cash In, Cash Out

How much cash is enough? It depends on how fast you spend it. But to keep a year's worth of living expenses in cash or near-cash (bonds, money market funds, and so on) is not foolish. At a minimum, you should have six months' worth of cash or near-cash in hand.

Cash is a terrible long-term investment, and treasury bonds aren't much better. But in terms of keeping calm so that you can make sensible decisions, there's no substitute for cash.

Personally, I get crazy when my cash reserves run low, which they can when employers are slow in paying me or I have sudden large expenses. For instance, I just had to have one of my embarrassingly many houses virtually demolished, re-piped, and re-floored because of a burst pipe -- not once, not twice, but three times in a short span.

You would be amazed at how much cash this can burn. And waiting for the insurance to pay is a recipe for heartache. As I write this, I realize I probably should've had even more cash reserves. I easily have 18 months' worth of cash, and it's the cash I think of when I'm worried, not my endless printouts of stock.

A Contagion of Panic

Here's another lesson:

3. Stocks don't always fall for a good reason.

Yes, there was cause for the Shanghai market to fall last week. It was up over 100 percent in approximately a year, and speculation was wild. But there was absolutely no reason at all for the cream of American stocks on the Dow and the S&P 500 to fall. It was just a contagion of panic.

If you read the newspapers, keep yourself well informed, and have your eyes open, you need to ask yourself if the economy looks as if it's in real trouble. If it doesn't look that way, don't sell unless you desperately need the money.

In fact, don't even sell then. Suppose there's a recession. I don't expect it, but it could happen. But suppose there is: Recessions in the past 20 years tend to be extremely short-lived. The lower stock prices that accompany a recession, and the lead-up to a recession, tend to be superb times to buy. If you can be patient, hang in there and buy when the market is low, over long periods of time, and you will be well ahead.

It's always better to buy when the market is low and the outlook is dour. If you have the smarts and the courage to do it, you'll be glad you did. People rarely make a lot of money buying at peaks; they always do well buying in valleys.

No Crystal Ball

4. Put not your trust in princes.

Alan Greenspan is a wonderful guy. He's been a friend of my little family forever, and he spoke glowingly at my father's memorial service. But he's not the Lord God. He can't see the future, and he has no data that other economists don't have.

Greenspan has a poor record indeed as a forecaster. He didn't see the collapse of 2000-2002 coming, and a few years ago he was warning that the great danger was deflation. He's a great man and was a magnificent Fed chair. But he doesn't have magical powers of foresight.

In fact, neither does anyone else, including me. The conclusion: Just keep buying at a measured pace, and if the market sinks a lot, buy more. I guarantee you that's how the big boys do it. The little guys sell out at the first sign of trouble -- the ones with the private jets hang on.

Two Last Lessons

And, finally:

5. DIVERSIFY.

I capitalize this on purpose. An investor's two best friends are time and diversification. Get the broadest possible market indexes. Spread yourself out over large and small caps. Have a large dollop of the developed foreign and a goodly chunk of the developing market. Yes, it'll be a rocky ride in China and Brazil, but over long periods you'll do great.

6. The long-term direction of the market is up.

It will fluctuate, as J.P. Morgan said, but the long-term trend is up. If you can patiently stay invested and take advantage of this long-term trend, you'll come out ahead. It may take some time, but short of nuclear war -- and in that case, there won't be a thing to worry about -- you'll make money if you stay in on a broadly diversified basis. You'll be wiped out if you sell on a panic basis.

So:

Have plenty of cash.

Be patient.

Never panic.

Buy when others are selling.

Diversify.

And, one last time, be patient. Do you think Warren Buffett was selling last week?

UBSS says no.

I hear ya, make money and be happy.

That is what hurt them during the last run. I called and the lady even told me they had moved from the North West to Florida because of the merger "at that time" which was back in what, October?

FMLY S-8 03/05/2007 for 63,000,000

Don't know how to read this one.

Ariad secures nearly $50M in new financing
Thursday February 15, 1:13 pm ET

Patent infringement litigation and increased costs related to stock options led to higher net losses for Ariad Pharmaceuticals Inc. in 2006.
The Cambridge, Mass. company (Nasdaq: ARIA - News) also announced on Thursday that has secured up to $50 million in new equity financing. That money will come in handy, because Ariad lost nearly $62 million during the fiscal year ending Dec. 31, up from a $55.5 million loss in fiscal 2005. Ariad lost $14.4 million during its fiscal 2006 fourth quarter, versus a $14.5 million net loss over the same period last year.

Ariad, which is focused on developing new cancer treatments, blamed the higher losses on expenses stemming from patent infringement litigation and new accounting requirements relating to stock options. Those expenses, however, were offset by lower research and development costs as the company reached later-stage clinical trials for its lead candidate, AP23573.

Ariad has also nailed down a $50 million equity financing commitment from Azimuth Opportunity Ltd. for up to $50 million of its common stock, which the company expects to use over the next 18 months.

Ariad, which as a drug developer doesn't generate significant revenue yet, says it spent $56 million to handle day-to-day operations in 2006. The company said it had just under $40 million in cash, equivalents and securities on hand as of Dec. 31.

Published February 15, 2007 by the Boston Business Journal

This is the run up from early Feb.

ARIAD Announces Global Phase 3 Clinical Trial Plans for AP23573 With Sarcoma Alliance and Achievement of Key Regulatory Milestones at Investor & Analyst Day
Thursday February 15, 11:00 am ET


CAMBRIDGE, Mass. and NEW YORK--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News) today announced that the Phase 3 clinical trial of oral AP23573, its novel mTOR inhibitor, will be conducted in patients with metastatic soft-tissue and bone sarcomas by the Sarcoma Alliance for Research through Collaboration (SARC) in cooperation with the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer (EORTC).

ARIAD also announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design and endpoints of this pivotal trial and that subsequently a Special Protocol Assessment (SPA) has been filed with the FDA for the trial based on the primary endpoint of progression-free survival (PFS). Similarly, a request for follow-up Protocol Assistance has been filed with the European Medicines Agency (EMEA). The FDA has previously granted fast-track status to AP23573 for the treatment of advanced sarcomas.

At the Company's Investor & Analyst Day held today in New York, Robert G. Maki, M.D., Ph.D., Deputy Director of SARC, Co-Director of the Adult Sarcoma Program at Memorial Sloan-Kettering Cancer Center, Assistant Professor of Medicine at Weill Medical College of Cornell University - and one of the lead investigators of the Phase 3 trial - discussed how SARC and EORTC will work together with ARIAD to leverage their world-renowned network of sarcoma experts and clinicians for participation in the collaborative Phase 3 trial. Dr. Maki also presented details concerning the design and anticipated conduct of the AP23573 pivotal trial.

Dr. Maki indicated that oral AP23573 would be compared to placebo in patients with metastatic sarcomas, who had a favorable response to first-line or second-line chemotherapy, a time frame when they normally would not receive other therapies. Approximately 500 patients at 50 to 75 sites worldwide will be randomized (1:1) to study drug or placebo. The trial is 99% powered to detect a 50% increase in median PFS comparing the AP23573-treated arm with the placebo arm. Two interim analyses are planned, and patient enrollment is expected to begin as soon as agreement on the SPA is reached with the FDA, which is anticipated by early second quarter 2007. Updated projections concerning the overall duration of the trial will be provided once patient enrollment is ongoing at multiple centers in the U.S. and Europe. The current target is to complete enrollment within approximately two years of entry of the first patient; the second interim analysis is planned to coincide with full patient enrollment.

"Our newly established partnership with SARC, as well as FDA agreement on our Phase 3 trial design, mark important achievements for the global development of AP23573. The SARC/EORTC collaboration gives us access to the leading sarcoma centers of excellence for our pivotal trial," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Having reached agreement with the FDA on the major issues relating to the trial, the SPA should provide us with further confirmation of the patient population, primary and secondary endpoints, sample size, and the statistical analysis plan and enable us to begin enrolling patients promptly in the registration trial."

Dr. Laurence H. Baker, Executive Director of SARC, Professor of Medicine and Pharmacology at the University of Michigan School of Medicine, Chairman of the Southwest Oncology Group (SWOG) and the principal investigator of the Phase 3 trial said, "SARC believes that this protocol achieved FDA agreement because it represents a consensus of an independent, international team of sarcoma experts. This is an historic opportunity for academic physicians to partner with industry to bring new, effective drugs to our sarcoma patients."

These announcements were made at the Company's Investor & Analyst Day held today in New York. The event featured interactive discussions with leading oncology experts specializing in the fields of sarcomas and leukemias. The discussion and slides used at the investor event will be available on the ARIAD website (http://www.ariad.com/investor) beginning today and will be archived for 30 days.

No but I am going to look. Will report back.

Almost everything yells reversal, but I must ask, do you know what cuased the sell off to start?

Defenite bounce off .0009 yesterday. I saw it late at .0012 and hesitated to buy.

CHNW is actually surprising me here. Chart isn't looking bad.

READ between the lines MHUS.

To do all this, we need to raise capital for this company.

Can you say Dilution?

We apply to get MHUS back onto the Bulletin Board.

Jeff is setting the stage for a Reverse Split.

ETIM is riding to high above those moving averages. RSI turned down, MACD adn STO about to curl over. A little pullback in the crystal ball?

Time to make the donuts.

The only catalyst that will get USXP to move is a RS and a nuclear reactor.

That is the whole point, he needs cash. Which is why a RS is perfect. Price goes up, runs a little, and dilution starts all over. That is how it works.

Stocks Steady Amid Mortgage Concerns
Monday March 5, 1:43 pm ET
By Madlen Read, AP Business Writer
Stocks Manage to Stabilize, Indexes Fluctuate As Dollar Falls Against Yen


NEW YORK (AP) -- Wall Street managed to stabilize itself Monday, although investors clearly were still nervous about mortgage defaults, a strengthening yen and tumbling stock markets abroad.
The major indexes fluctuated as investors tried to size up where the market was headed, and as traders swooped in to take advantage of stocks left severely depressed by last week's big decline.

"Probably it's better to save any judgment on this market today until the last half hour," said Philip S. Dow, managing director of equity strategy at RBC Dain Rauscher in Minneapolis, noting that little has changed in terms of economic fundamentals, but that the market is still very volatile.

The concern about losses over soured subprime loans -- loans to customers with poor credit ratings -- was one of the many factors behind Wall Street's selloff. That worry was rekindled Monday when HSBC Holdings PLC, Europe's largest bank, said its 2006 earnings rose 5 percent but that it suffered $10.6 billion on losses on bad loans from its U.S. subprime mortgage operations.

A rising yen added to jitters over an erosion of the yen carry trade, which is the process of borrowing the low-yielding yen to acquire assets in other currencies with greater yields. A slowdown could hurt liquidity worldwide. By early afternoon, the U.S. dollar was below 116 yen, trading near three-month lows having fallen from above 120 yen less than a week ago.

The Institute for Supply Management's report on the services sector failed to inject much confidence in the market. The index registered at 54.3 for February, lower than analysts' forecast of 57.5 and January's reading of 59.0. Still, the reading above 50 indicates that U.S. service industries continue to grow, albeit at a modest pace.

In early afternoon trading, the Dow Jones industrial average was up 4.00, or 0.03 percent, at 12,118.10, having swung 75 points lower and 75 higher in earlier trading.

Broader stock indicators were lower. The Standard & Poor's 500 index was down 4.44, or 0.32 percent, at 1,382.73, and the Nasdaq composite index fell 13.88, or 0.59 percent, to 2,354.12.

Bond prices fell slightly, with the yield on the benchmark 10-year Treasury note at 4.51 percent, up from 4.50 percent late Friday. The dollar was higher against other major currencies except for the yen. Gold, though traditionally a safe-haven investment, continued to slide.

Oil prices dropped sharply, losing $1.76 to trade at $59.88 a barrel on the New York Mercentile Exchange due to concerns about how demand will fare if the world's major economies cool off.

Stock investors appeared to have been somewhat consoled by comments attributed to U.S. Treasury Secretary Henry Paulson by Japan's finance minister, Koji Omi. Neither Omi nor Paulson, who began a three-nation Asian tour in Tokyo on Monday, were concerned by the swings in regional stock markets, Omi told reporters in Tokyo. Both men contend the market mechanism was functioning well, Omi said.

Still, Asian and European stocks left U.S. investors nervous. The Nikkei fell for the fifth straight session to close down 3.3 percent, Hong Kong's Hang Seng index fell 4 percent and the Shanghai Composite Index, which has been volatile in recent weeks, fell 1.6 percent.

In Europe, Britain's FTSE 100 dropped 0.94 percent, Germany's DAX index was down 1.04 percent, and France's CAC-40 was down 0.73 percent.

The Russell 2000 index of smaller companies was down 8.74, or 1.13 percent, at 766.60.

Declining issues outnumbered advancers by about 3 to 1 on the New York Stock Exchange, where volume came to 1.10 billion shares.

Market participants are bracing for a rocky week, especially as investors await the Labor Department's jobs data, which will be released on Friday. So far, economic data has been coming in mixed, suggesting a slowing growth but not recession.

"We saw the ISM come in lower than expected, but the economy is slowing, and that's fine," said Scott Wren, senior equity strategist for A.G. Edwards & Sons. The ISM said the service sector, which represents about 80 percent of the nation's economic activity, saw nine of its industries grow and nine contract.

Investors were also watching for clues to the economy's health in speeches Monday by Federal Reserve officials. St. Louis Fed President William Poole, a voting member of the interest rate-setting Federal Open Market Committee, echoed recent statements by Fed Chairman Ben Bernanke Monday, saying the outlook for the economy is not as bad as the market's recent downturn suggests, and that inflation remains a concern for policy makers.

Though the markets have been tumbling, market watchers note that merger and acquisition activity is still strong -- a positive sign for stocks.

Pathmark Stores Inc. rose $1.20, or 10.7 percent, to $12.45 after A&P supermarket operator Great Atlantic & Pacific Tea Co. agreed to buy Pathmark for $1.3 billion in cash and stock. In a somewhat unusual occurence for a company making an acqusition, investors bid Great Atlantic & Pacific higher; the stock was up $1.02, or 3.3 percent, at $31.88.

The subprime mortgage sector, already dragged down by concerns that too many people are defaulting, was kicked down further when New Century Financial Corp., the second-largest subprime lender, said late Friday that a federal prosecutor and the New York Stock Exchange are conducting investigations into movements in the company's stock price. New Century fell $8.80, or 60 percent, to $5.85.

Also spooking investors was Fremont General Corp., which said it is planning to sell its subprime residential real-estate lending business. Fremont fell $2.13, or 24 percent, to $6.58.

New York Stock Exchange: http://www.nyse.com

Nasdaq Stock Market: http://www.nasdaq.com

I really hate to bash but that is what Jeff does. He dilutes and reverse splits. I found out to late who he was and what his history is like.

Are we expecting news?

Thanks, microcap didn't pick that up for some reason.

It usually gets brought back up. Those .005s are getting thick though.

Yup, it was ugly.

GZFX filed S-8 on 2/14/07

I use Alphatrade. Sorry.

I was calling about horrible fills.

I only got 5. I must be a chump.

They have to be selling into news.

SUNW days range: 6.01 - 6.14

At least you are honest. I sold out again. This is screaming RS which Jeff is known to do.

Wow. Where did all the longs go?

SHoooooooooooRT?

Stocks head toward lower opening By TIM PARADIS, AP Business Writer

NEW YORK - Wall Street appeared headed for a lower opening Monday as stock markets around the world suffered further selloffs.

The overseas pullback, in which Japan's Nikkei stock average saw its biggest one-day drop since June, resembled the selling that triggered the recent unease in world markets last Tuesday.

The weekend respite appeared to do little to ease concerns about losses over soured loans by subprime lenders. HSBC Holdings PLC, Europe's largest bank, on Monday said its 2006 profits rose 5 percent but that it booked $10.6 billion on losses on bad loans from its U.S. subprime mortgage operations.

A rising yen stoked further concern about an erosion in the yen carry trade, which refers to the process of borrowing yen to acquire assets with greater yields in other currencies. A slowdown could hurt liquidity worldwide. On Monday, the U.S. dollar fell to about 115 yen from above 120 yen less than a week ago.

Dow Jones industrials futures fell 93 points, or 0.82 percent; Nasdaq 100 futures slipped 15.2 points, or 0.58 percent, and Standard & Poor's 500 index futures fell 10.3 points, or 0.84 percent.

After sharp declines last week, the major indexes are now lower for the year, with the Dow down 3.3 percent, the Standard & Poor's 500 index down 4.4 percent and the Nasdaq composite index lower by 5.9 percent.

Drops in Asia and Europe appeared to leave U.S. investors unnerved. The Nikkei closed down 3.3 percent, Hong Kong's Hang Seng index fell 4 percent and the Shanghai Composite Index, which has proven volatile in recent weeks, fell 1.6 percent. In Europe, the major indexes were down by more than 1 percent.

Wall Street begins the week with little economic data that could perhaps ease concerns among U.S. investors about the stamina of the U.S. economy. One noteworthy report due, however, is from the Institute for Supply Management, which is scheduled to report its index on the services sector. The market is expecting the reading on the largest slice of the economy to come in at 57.5, down slightly from 59.0 in January.

Investors will also be keeping tabs on the moves of U.S. Treasury Secretary Henry Paulson, who began a three-nation Asian tour in Tokyo on Monday.

I bet those who sold .003 the day before the run started are hating life right now.

Think it can sustain the run? Will it never fill that gap?

Just for a breif moment. That would have been nice to load up on about 10k shares.